Literature DB >> 32304619

Best treatments available for distal acquired lacrimal obstruction: A systematic review and meta-analysis.

Alessandro Vinciguerra1, Alessandro Nonis2, Antonio Giordano Resti3, Mario Bussi1, Matteo Trimarchi1.   

Abstract

BACKGROUND: Epiphora is a common clinical sign whose primary cause is post-canalicular lacrimal obstruction. Treatment is both surgical and non-surgical. In the literature, there is some evidence to suggest that some treatments are superior to others, but there are no direct comparative data in this regard. OBJECTIVE OF REVIEW: To analyse the success rates of all available treatments to resolve post-canalicular acquired lacrimal obstruction. TYPE OF REVIEW: Systematic review and meta-analysis. SEARCH STRATEGY: A literature search was conducted in the US National Library of Medicine (PubMed), EMBASE, SCOPUS and Cochrane databases with a final search performed in January 2020. EVALUATION
METHOD: The search strategy identified articles published later than 2000 with at least 50 procedures performed both surgically (external dacryocystorhinostomy [EXT-DCR], endoscopic dacryocystorhinostomy [END-DCR] and transcanalicular laser dacryocystorhinostomy [TCL-DCR]) and non-surgically (balloon dacryoplasty [DCP], probing-stenting [SP] and polyurethane stent [PoS]). The primary outcome was functional success, defined as symptom resolution or less than MUNK 2 scale; in addition to this, the influence of adjunctive treatments, such as application of mitomycin C and post-procedural silicone stenting, was evaluated.
RESULTS: In total, 14 958 papers were selected, 440 of which were reviewed after screening; 55 were included after full-text review, which involved 9337 procedures. Mean success rate was 48.9% (35.7%-62.3%) for DCP, 54.4% (41.8%-66.5%) for SP, 73.6% (59.7%-84%) for PoS, 80% (75.1%-84%) for TCL-DCR, 89.8% (83.3%-93.9%) for EXT-DCR and 89.5% (87.2%-91.5%) for END-DCR. Among all procedures, a difference was noted between DCP and END-DCR (P < .001), DCP and EXT-DCR (P < .001), SP and END-DCR (P < .001), SP and EXT-DCR (P < .001), END-DCR and PoS (P = .016), and END-DCR and TCL-DCR (P = .001); no differences were noted between END-DCR and EXT-DCR (P = 1.00), EXT-DCR and PoS (P = .121) and EXT-DCR and TCL-DCR (P = .223). Considering surgical procedures, no differences were seen if a silicone stenting was applied, whereas, due to heterogeneity of the literature data, no statistical analysis was feasible for application of mitomycin C.
CONCLUSIONS: Our analyses suggest that, among all procedures available, END-DCR and EXT-DCR should be considered as treatments of choice to resolve distal acquired lacrimal obstruction.
© 2020 John Wiley & Sons Ltd.

Entities:  

Keywords:  dacryocystorhinostomy; endoscopic sinus surgery; ophthalmology; outcomes; systematic reviews

Year:  2020        PMID: 32304619     DOI: 10.1111/coa.13551

Source DB:  PubMed          Journal:  Clin Otolaryngol        ISSN: 1749-4478            Impact factor:   2.597


  4 in total

1.  A simple and efficient technique for suturing and knotting during endoscopic dacryocystorhinostomy.

Authors:  Rongxin Chen; Shu Liu; Aixin Jiang; Aizezi Wumaier; Yuanxia Yang; Xinyue Yu; Ziwei Meng; Yuxiang Mao; Xuanwei Liang
Journal:  Int Ophthalmol       Date:  2022-07-15       Impact factor: 2.029

2.  Dacryoendoscopy-assisted incision of Hasner's valve under nasoendoscopy for membranous congenital nasolacrimal duct obstruction after probing failure: a retrospective study.

Authors:  Yue Li; Min Wei; Xueru Liu; Leilei Zhang; Xuefei Song; Caiwen Xiao
Journal:  BMC Ophthalmol       Date:  2021-04-19       Impact factor: 2.209

3.  Detection & analysis of inflammatory cytokines in tears of patients with lacrimal duct obstruction.

Authors:  Dan Wang; Nan Xiang; Wei Kun Hu; Ban Luo; Xiang Tian Xiao; Yin Zhao; Bin Li; Rong Liu
Journal:  Indian J Med Res       Date:  2021-06       Impact factor: 5.274

4.  Long-term results of a balloon-assisted endoscopic approach in failed dacryocystorhinostomies.

Authors:  Alessandro Vinciguerra; Matteo Trimarchi; Pietro Indelicato; Antonio Giordano Resti; Mario Bussi
Journal:  Eur Arch Otorhinolaryngol       Date:  2021-07-12       Impact factor: 3.236

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.